NDA 020541 · Ani Pharms
Arimidex
Anastrozole · Oral · Aromatase Inhibitor
NovelAccelerated approvalLast checked: Nov 19, 2026Latest source record: Dec 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Dec 27, 1995
Approved uses
6
Original approval plus efficacy supplements
Registered trials
422
120 Phase 3, 66 recruiting
FAERS reports
37,157
25,421 serious, 2,478 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 2, 2026.
ARIMIDEX is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX ( 1.3 ) 1.1 Adjuvant Treatment ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.
Mechanism: The growth of many cancers of the breast is stimulated or maintained by estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 18, 2011 Supplement 26 · Efficacy LabelLetter
- Apr 30, 2009 Supplement 24 · Efficacy LabelLetter
- Sep 16, 2005 Supplement 16 · Efficacy LabelLetter
- Sep 5, 2002 Supplement 10 · Efficacy · priority review ReviewLabelLetter
- Sep 1, 2000 Supplement 6 · Efficacy ReviewLabelLetter
- Dec 27, 1995 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- ARIMIDEX · ANASTROZOLE 1MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Anastrozole" as an intervention, any sponsor and status, largest first.
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Pivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00310180 · 10,273 participants · Start Apr 7, 2006 · Primary completion Mar 2, 2018
Drug: Anastrozole; Exemestane and 2 more · For: Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7 and 4 more
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 1,222 sites in all
- ATAC - Pharmacokinetics (PK) Sub-ProtocolPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00784862 · 9,358 participants · Start Jun 1998
Drug: Anastrozole; Tamoxifen · For: Breast Cancer
- ATAC - Arimidex, Tamoxifen Alone or in CombinationPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00849030 · 9,358 participants · Start Jul 1996 · Primary completion Jun 2001
Drug: Anastozole (Arimidex); Tamoxifen (Nolvadex) and 2 more · For: Breast Cancer
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05514054 · 8,000 participants (planned) · Start Oct 4, 2022 · Primary completion Oct 2027
Drug: Imlunestrant; Tamoxifen and 3 more · For: Breast Neoplasms
Sites: Daphne, Alabama; Huntsville, Alabama; Mobile, Alabama · 672 sites in all
- Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00066573 · 7,576 participants · Start Jun 6, 2003 · Primary completion Nov 7, 2010
Drug: anastrozole; exemestane · For: Breast Cancer
Sites: Calgary, Canada; Lethbridge, Canada; Kelowna, Canada · 39 sites in all
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05952557 · 5,511 participants · Start Oct 5, 2023 · Primary completion Mar 4, 2030
Drug: Camizestrant; Tamoxifen and 4 more · For: Breast Cancer, Early Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 661 sites in all
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerPivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07349069 · 5,500 participants (planned) · Start Mar 4, 2026 · Primary completion Dec 2030
Drug: HRS-8080 Tablets; Letrozole tablets and 3 more · For: Breast Cancer
Sites: Nanjing, China; Shanghai, China
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03701334 · 5,101 participants · Start Dec 7, 2018 · Primary completion May 29, 2030
Drug: Ribociclib · For: Early Breast Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Jonesboro, Arkansas · 387 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue3,541
- arthralgia3,276
- nausea2,844
- alopecia2,620
- diarrhoea2,441
- pain1,887
- headache1,836
- asthenia1,647
- dyspnoea1,620
- dizziness1,571
- pain in extremity1,461
- hot flush1,445
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 278 |
| 2005 | 385 |
| 2006 | 549 |
| 2007 | 1,232 |
| 2008 | 1,491 |
| 2009 | 1,838 |
| 2010 | 1,308 |
| 2011 | 1,385 |
| 2012 | 1,449 |
| 2013 | 965 |
| 2014 | 994 |
| 2015 | 1,268 |
| 2016 | 1,609 |
| 2017 | 1,936 |
| 2018 | 2,254 |
| 2019 | 2,548 |
| 2020 | 2,234 |
| 2021 | 2,081 |
| 2022 | 2,315 |
| 2023 | 2,611 |
| 2024 | 2,273 |
| 2025 | 2,267 |
| 2026 | 1,886 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Arimidex (Anastrozole)
2024 spending
$3.5M
Beneficiaries
279
1,348 claims
Per beneficiary
$12,683
$50.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,560,786 |
| 2021 | $4,961,362 |
| 2022 | $4,272,365 |
| 2023 | $3,989,944 |
| 2024 | $3,538,425 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Hortobagyi GN, Lacko A, Sohn J, et al. · Ann Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP, Toi M, Campone M, et al. · J Clin Oncol 2017 · Clinical Trial, Phase III, Multicenter Study
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
Goetz MP, Toi M, Huober J, et al. · Ann Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Slamon D, Lipatov O, Nowecki Z, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
Crown J, Stroyakovskii D, Yardley DA, et al. · ESMO Open 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Fasching PA, Stroyakovskiy D, Yardley DA, et al. · JAMA Oncol 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.